ASH News Daily - Saturday, December 10, 2011 - (Page B-16)

ASH NewS DAily ® Now Recruiting…… A New Clinical Trial for Patients with High-risk Smoldering Multiple Myeloma FocuS on early-career hematologiStS 2011 Special Events and Services for Trainees An important part of ASH’s mission is to support education and training in hematology. ASH provides valuable learning opportunities for hematology fellows, residents, medical students, and trainees during this year’s annual meeting. If you are a hematologist in training, plan to attend one or all of these events. derson Cancer Center John C. Byrd, MD, The Ohio State University Industry Careers Eric Sievers, MD, Seattle Genetics, Inc. Jerry Zeldis, MD, PhD, Celgene Corporation Lilli Petruzzelli, MD, PhD, Novartis Government (FDA/NIH) Careers Keith Hoots, MD, National Heart, Lung, and Blood Institute Ann Farrell, MD, FDA Susan Shurin, MD, National Heart, Lung, and Blood Institute Pediatric Hematology/ Oncology Careers David Williams, MD, Children’s Hospital, Boston Jorge Di Paola, MD, University of Iowa Kathleen Sakamoto, MD, PhD, University of California, Los Angeles Frank Smith, MD, Children’s Hospital, Cincinnati PhD Careers David Bodine, PhD, National Institutes of Health Hal Broxmeyer, PhD, Indiana University Nancy Speck, PhD, University of Pennsylvania Varsha Gandhi, PhD, M.D. Anderson Cancer Center Private Practice Careers Elaine Gayle Chottiner, MD, Ann Arbor Hematology Oncology Associates L. Crain Garrot, MD, Atlanta, GA Gerald J. Robbins, MD, Florida Cancer Institute Judith Kleinerman, MD, Medical Specialists Of Taunton Residents and Medical Students Academic Program in Hematology and Hematology/Oncology Elaine Muchmore, MD, University of California, San Diego Patrick Leavey, MD, The University of Texas Southwestern Reed Drews, MD, Beth Israel Deaconess Medical Center Marc Kahn, MD, Tulane University »» TRAINEES Page B-30 About Smoldering Multiple Myeloma (SMM) Smoldering multiple myeloma (SMM) is an asymptomatic condition that over time will transition into the malignant disease of multiple myeloma (MM). Study Overview Janssen Research, a unit of Centocor Research and Development, Inc., is conducting a study on SMM. In a global study 50 high-risk SMM subjects will be randomized to study drug and 50 subjects will be randomized to placebo (same drug without active ingredient). The study is double-blind, that is both doctors and patients will not know if the study drug or placebo will be given. The study intends to evaluate and/or follow subjects for 4-5 years. Career-Development Lunch Sessions Today, 11:15 a.m. - 12:15 p.m. Manchester Grand Hyatt Manchester Ballroom AB and DE The trainee career-development lunch sessions are roundtable discussions during which trainees will have an opportunity to discuss specific questions with an expert from the field in which they have expressed an interest. There are two rooms and each faculty member has a table (each holding approximately 6-10 people); there are two tables per room, per topic. Trainees will interact informally with the faculty where they may ask questions about career-development issues specific to their area of hematology. Adult Hematology/ Clinical Research Careers Daniel J. DeAngelo, MD, PhD, Dana-Farber Cancer Institute Daniel Weisdorf, MD, University of Minnesota Eric J. Feldman, MD, Cornell Medical Center Wendy Stock, MD, University of Chicago Hospital-Based HematologyHemapheresis/BMT/ Hematopathology Careers Elaine Jaffe, MD, National Institutes of Health Jonathan Said, MD, UCLA Gary Schiller, MD, UCLA Andrew Leavitt, MD, University of California, San Francisco Laboratory & Translational Hematology Careers Bob Negrin, MD, Stanford University C. Anthony Blau, MD, University of Washington Jeffrey Molldrem, MD, M.D. An- Primary Objective The primary objective of the study is to evaluate the 1-year progression-free survival (PFS) rate in patients with smoldering multiple myeloma (MM) with an investigational medication. Major Inclusion Criteria ■ Diagnosis of SMM for < 4 years ■ Diagnosis of high-risk SMM; ■ ECOG Performance score of 0 or 1 Study Design 100 patients(1:1) Receive investigational medication as an infusion every 4 weeks Receive placebo as an infusion every 4 weeks About the Investigative Medication The investigational medication is a monoclonal antibody that binds to IL-6. For more information, please email: mbalvers@its.jnj.com or btromp@its.jnj.com SMM-2001-ENG15 Version 1.0, 17JUN2011

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com